Intravitreal Dexamethasone Implant as a Sustained Release Drug Delivery Device for the Treatment of Ocular Diseases: A Comprehensive Review of the Literature
Drug delivery into the vitreous chamber remains a great challenge in the pharmaceutical industry due to the complex anatomy and physiology of the eye. Intravitreal injection is the mainstream route of drug administration to the posterior segment of the eye. The purpose of this review is to assess the current literature about the widening use of the intravitreal 0.7 mg dexamethasone (Dex) implant, and to provide a comprehensive collection of all the ocular disorders that benefit from Dex administration. Although anti-vascular endothelial growth-factors (VEGFs) have been largely indicated as a first-choice level, the Dex implant represents an important treatment option, especially in selected cases, such as vitrectomized eyes or patients in whom anti-VEGF failed or are contraindicated. In this article, the safety profile as well as the list of the possible complications related to intravitreal Dex injection are also discussed..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Pharmaceutics - 12(2020), 8, p 703 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Claudio Iovino [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Corticosteroids |
|---|
| doi: |
10.3390/pharmaceutics12080703 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ02283642X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ02283642X | ||
| 003 | DE-627 | ||
| 005 | 20240412222909.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/pharmaceutics12080703 |2 doi | |
| 035 | |a (DE-627)DOAJ02283642X | ||
| 035 | |a (DE-599)DOAJf96b41306875457da75c61da5f934938 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RS1-441 | |
| 100 | 0 | |a Claudio Iovino |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intravitreal Dexamethasone Implant as a Sustained Release Drug Delivery Device for the Treatment of Ocular Diseases: A Comprehensive Review of the Literature |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Drug delivery into the vitreous chamber remains a great challenge in the pharmaceutical industry due to the complex anatomy and physiology of the eye. Intravitreal injection is the mainstream route of drug administration to the posterior segment of the eye. The purpose of this review is to assess the current literature about the widening use of the intravitreal 0.7 mg dexamethasone (Dex) implant, and to provide a comprehensive collection of all the ocular disorders that benefit from Dex administration. Although anti-vascular endothelial growth-factors (VEGFs) have been largely indicated as a first-choice level, the Dex implant represents an important treatment option, especially in selected cases, such as vitrectomized eyes or patients in whom anti-VEGF failed or are contraindicated. In this article, the safety profile as well as the list of the possible complications related to intravitreal Dex injection are also discussed. | ||
| 650 | 4 | |a corticosteroids | |
| 650 | 4 | |a drug delivery systems | |
| 650 | 4 | |a intravitreal dexamethasone implant | |
| 650 | 4 | |a intravitreal injections | |
| 650 | 4 | |a Ozurdex | |
| 653 | 0 | |a Pharmacy and materia medica | |
| 700 | 0 | |a Rodolfo Mastropasqua |e verfasserin |4 aut | |
| 700 | 0 | |a Marco Lupidi |e verfasserin |4 aut | |
| 700 | 0 | |a Daniela Bacherini |e verfasserin |4 aut | |
| 700 | 0 | |a Marco Pellegrini |e verfasserin |4 aut | |
| 700 | 0 | |a Federico Bernabei |e verfasserin |4 aut | |
| 700 | 0 | |a Enrico Borrelli |e verfasserin |4 aut | |
| 700 | 0 | |a Riccardo Sacconi |e verfasserin |4 aut | |
| 700 | 0 | |a Adriano Carnevali |e verfasserin |4 aut | |
| 700 | 0 | |a Rossella D’Aloisio |e verfasserin |4 aut | |
| 700 | 0 | |a Alessio Cerquaglia |e verfasserin |4 aut | |
| 700 | 0 | |a Lucia Finocchio |e verfasserin |4 aut | |
| 700 | 0 | |a Andrea Govetto |e verfasserin |4 aut | |
| 700 | 0 | |a Stefano Erba |e verfasserin |4 aut | |
| 700 | 0 | |a Giacinto Triolo |e verfasserin |4 aut | |
| 700 | 0 | |a Antonio Di Zazzo |e verfasserin |4 aut | |
| 700 | 0 | |a Matteo Forlini |e verfasserin |4 aut | |
| 700 | 0 | |a Aldo Vagge |e verfasserin |4 aut | |
| 700 | 0 | |a Giuseppe Giannaccare |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Pharmaceutics |d MDPI AG, 2010 |g 12(2020), 8, p 703 |w (DE-627)DOAJ000114154 |x 19994923 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:8, p 703 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/pharmaceutics12080703 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/f96b41306875457da75c61da5f934938 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/1999-4923/12/8/703 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1999-4923 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2020 |e 8, p 703 | ||